BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22712834)

  • 21. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency.
    Park JW; Kim YK; Bae EH; Ma SK; Kim SW
    Clin Biochem; 2012 Jul; 45(10-11):740-4. PubMed ID: 22503879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma.
    Giarin MM; Giaccone L; Sorasio R; Sfiligoi C; Amoroso B; Cavallo F; Cipriani A; Palumbo A; Boccadoro M
    Clin Chem; 2009 Aug; 55(8):1510-6. PubMed ID: 19520760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the Diagnostic Value of sFLC and Other Indicators in the Detection of M Protein in LCMM.
    Wang J; Zhao Y; Ren Z; Sun A; Huang Z; Li X
    Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
    El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
    Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
    Yağcı M; Karakaya F; Suyanı E; Haznedar R
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma].
    Li L; Jiang H; Fu WJ; Du J; He HY; Lu J; An R; He J; Zhang H; Zhao YY; Wu H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):321-326. PubMed ID: 31104445
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
    Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study.
    Cotten SW; Shajani-Yi Z; Cervinski MA; Voorhees T; Tuchman SA; Korpi-Steiner N
    Clin Biochem; 2018 Aug; 58():100-107. PubMed ID: 29885308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].
    Zhu GQ; Fu X; Ren YS; Wang YS; Wang SL; Wang LC; Lin J; An G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1209-1215. PubMed ID: 34362504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical course and prognosis of non-secretory multiple myeloma.
    Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
    Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.
    Campbell JP; Heaney JL; Shemar M; Baldwin D; Griffin AE; Oldridge E; Goodall M; Afzal Z; Plant T; Cobbold M; Jefferis R; Jacobs JF; Hand C; Drayson MT
    Clin Chem Lab Med; 2017 Mar; 55(3):424-434. PubMed ID: 27505089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.
    Bossuyt X; Delforge M; Reynders M; Dillaerts D; Sprangers B; Fostier K; Poesen K; Vercammen M
    Leukemia; 2018 Aug; 32(8):1815-1818. PubMed ID: 29674643
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
    Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
    Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
    van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
    Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of serum free light chain in patients with multiple myeloma].
    Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of immunoglobulin heavy/light chain detection on the minimal residual disease monitoring in IgG multiple myeloma patients].
    Zhang H; Zhou L; Li R; He J; Peng Z; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):95-8. PubMed ID: 25778881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.